Vertex PharmaceuticalsVRTX
About: Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease. Additionally, Vertex is evaluating small-molecule inhibitors targeting acute and chronic pain using nonopioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Employees: 5,400
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
22% more call options, than puts
Call options by funds: $881M | Put options by funds: $721M
8% more repeat investments, than reductions
Existing positions increased: 605 | Existing positions reduced: 558
4% less capital invested
Capital invested by funds: $111B [Q2] → $107B (-$4.12B) [Q3]
3% less funds holding
Funds holding: 1,523 [Q2] → 1,483 (-40) [Q3]
2.8% less ownership
Funds ownership: 92.31% [Q2] → 89.5% (-2.8%) [Q3]
13% less funds holding in top 10
Funds holding in top 10: 32 [Q2] → 28 (-4) [Q3]
26% less first-time investments, than exits
New positions opened: 115 | Existing positions closed: 155
Research analyst outlook
18 Wall Street Analysts provided 1 year price targets over the past 3 months
18 analyst ratings
Citigroup Geoff Meacham 42% 1-year accuracy 10 / 24 met price target | 23%upside $575 | Buy Initiated | 14 Nov 2024 |
Canaccord Genuity Whitney Ijem 43% 1-year accuracy 16 / 37 met price target | 12%downside $408 | Sell Maintained | 6 Nov 2024 |
Scotiabank Greg Harrison 60% 1-year accuracy 15 / 25 met price target | 4%upside $486 | Sector Perform Maintained | 5 Nov 2024 |
UBS Colin Bristow 25% 1-year accuracy 4 / 16 met price target | 26%upside $586 | Buy Maintained | 5 Nov 2024 |
Cantor Fitzgerald Olivia Brayer 60% 1-year accuracy 15 / 25 met price target | 3%upside $480 | Overweight Reiterated | 5 Nov 2024 |
Financial journalist opinion
Based on 35 articles about VRTX published over the past 30 days
